HRP20240713T1 - Polimorfi od (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden- 1-il)-1-metil-1h-pirazol-4-karboksamida - Google Patents
Polimorfi od (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden- 1-il)-1-metil-1h-pirazol-4-karboksamida Download PDFInfo
- Publication number
- HRP20240713T1 HRP20240713T1 HRP20240713TT HRP20240713T HRP20240713T1 HR P20240713 T1 HRP20240713 T1 HR P20240713T1 HR P20240713T T HRP20240713T T HR P20240713TT HR P20240713 T HRP20240713 T HR P20240713T HR P20240713 T1 HRP20240713 T1 HR P20240713T1
- Authority
- HR
- Croatia
- Prior art keywords
- polymorph
- polymorphic form
- maxima
- degrees
- ethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875350P | 2019-07-17 | 2019-07-17 | |
| PCT/US2020/042387 WO2021011807A1 (en) | 2019-07-17 | 2020-07-16 | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| EP20753562.6A EP3999180B1 (en) | 2019-07-17 | 2020-07-16 | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240713T1 true HRP20240713T1 (hr) | 2024-09-13 |
Family
ID=71995103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240713TT HRP20240713T1 (hr) | 2019-07-17 | 2020-07-16 | Polimorfi od (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden- 1-il)-1-metil-1h-pirazol-4-karboksamida |
Country Status (25)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006296YA (en) | 2018-01-19 | 2020-08-28 | Cytokinetics Inc | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス, インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| MX2022000498A (es) | 2019-07-17 | 2022-02-03 | Cytokinetics Inc | Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida. |
| KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| EP4370116B1 (en) | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| JP2024530111A (ja) | 2021-08-03 | 2024-08-16 | サイトキネティックス, インコーポレイテッド | アフィカムテンを調製するための工程 |
| US20240091203A1 (en) | 2022-07-20 | 2024-03-21 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| JP2025525913A (ja) | 2022-08-04 | 2025-08-07 | サイトキネティックス, インコーポレイテッド | 閉塞性肥大型心筋症を治療するための方法 |
| WO2024134498A1 (en) | 2022-12-22 | 2024-06-27 | Assia Chemical Industries Ltd. | Solid state forms of aficamten and process for preparation thereof |
| CN120712262A (zh) * | 2023-03-02 | 2025-09-26 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| WO2025198687A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006296YA (en) * | 2018-01-19 | 2020-08-28 | Cytokinetics Inc | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP2024530111A (ja) * | 2021-08-03 | 2024-08-16 | サイトキネティックス, インコーポレイテッド | アフィカムテンを調製するための工程 |
-
2020
- 2020-07-16 LT LTEPPCT/US2020/042387T patent/LT3999180T/lt unknown
- 2020-07-16 FI FIEP20753562.6T patent/FI3999180T3/fi active
- 2020-07-16 PT PT207535626T patent/PT3999180T/pt unknown
- 2020-07-16 DK DK20753562.6T patent/DK3999180T3/da active
- 2020-07-16 AU AU2020313965A patent/AU2020313965B2/en active Active
- 2020-07-16 HR HRP20240713TT patent/HRP20240713T1/hr unknown
- 2020-07-16 HU HUE20753562A patent/HUE066891T2/hu unknown
- 2020-07-16 WO PCT/US2020/042387 patent/WO2021011807A1/en not_active Ceased
- 2020-07-16 RS RS20240598A patent/RS65611B1/sr unknown
- 2020-07-16 SI SI202030443T patent/SI3999180T1/sl unknown
- 2020-07-16 MX MX2022000504A patent/MX2022000504A/es unknown
- 2020-07-16 BR BR112022000494A patent/BR112022000494A2/pt unknown
- 2020-07-16 IL IL289875A patent/IL289875B1/en unknown
- 2020-07-16 CA CA3144975A patent/CA3144975A1/en active Pending
- 2020-07-16 SM SM20240224T patent/SMT202400224T1/it unknown
- 2020-07-16 ES ES20753562T patent/ES2980885T3/es active Active
- 2020-07-16 PL PL20753562.6T patent/PL3999180T3/pl unknown
- 2020-07-16 KR KR1020227004639A patent/KR20220084008A/ko active Pending
- 2020-07-16 EP EP24174636.1A patent/EP4487911A1/en active Pending
- 2020-07-16 CN CN202411172308.4A patent/CN118908951A/zh active Pending
- 2020-07-16 US US17/627,599 patent/US20220315571A1/en active Pending
- 2020-07-16 JP JP2022502215A patent/JP7624431B2/ja active Active
- 2020-07-16 CN CN202411172321.XA patent/CN119119018A/zh active Pending
- 2020-07-16 PH PH1/2022/550123A patent/PH12022550123A1/en unknown
- 2020-07-16 TW TW109124093A patent/TWI865562B/zh active
- 2020-07-16 EP EP20753562.6A patent/EP3999180B1/en active Active
- 2020-07-16 CN CN202080059660.0A patent/CN114555590B/zh active Active
-
2022
- 2022-01-10 CL CL2022000054A patent/CL2022000054A1/es unknown
-
2025
- 2025-01-20 JP JP2025007662A patent/JP7755090B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3999180T3 (fi) | (r)-n-(5-(5-etyyli-1,2,4-oksadiatsol-3-yyli)-2,3-dihydro-1h-inden-1–yyli)-1–metyyli-1h-pyratsoli-4-karboksamidin polymorfeja | |
| JP2022540668A5 (cg-RX-API-DMAC10.html) | ||
| CN103221047B (zh) | 化合物和方法 | |
| WO2005058848A1 (en) | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists | |
| EP1625123A2 (en) | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists | |
| CN100509789C (zh) | 替米沙坦的晶体钠盐及其作为血管紧张素的拮抗药的用途 | |
| WO1997046556A1 (en) | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | |
| WO2011144338A1 (en) | Pyrazole derivatives as s1p1 agonists | |
| EP1670463A2 (en) | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | |
| CN116547270A (zh) | 4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基甲酰基)双环[2.2.1]庚-2-基)氨基甲酰基)苯氧基)-1-甲基环己烷-1-甲酸衍生物以及类似化合物作为rxfp1调节剂用于治疗心力衰竭 | |
| JP5483880B2 (ja) | イミノピリジン誘導体およびその用途 | |
| WO2012012477A1 (en) | Substituted 3-phenyl-1,2,4-oxadiazole compounds | |
| TWI895453B (zh) | 雜環類化合物的晶型及其製備方法和應用 | |
| TWI922665B (zh) | (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式 | |
| JP2011518766A (ja) | イミノピリジン誘導体およびその用途 | |
| WO2004046107A1 (en) | Indole derivatives as somatostatin agonists or antagonists | |
| JP2022540678A5 (cg-RX-API-DMAC10.html) | ||
| DK2207776T3 (en) | Drug active in neuropathic pain | |
| JP2018521001A (ja) | 化合物 (s)−3−{4−[5−(2−シクロペンチル−6−メトキシ−ピリジン−4−イル)−[1,2,4]オキサジアゾール−3−イル]−2−エチル−6−メチル−フェノキシ}−プロパン−1,2−ジオールの結晶形 | |
| AU2015247575C1 (en) | Polycyclic hERG activators | |
| JPS61257983A (ja) | 1,4−ジヒドロピリジン及びこれを有効成分とする医薬組成物 | |
| JPH08507299A (ja) | ヒドロキシメチルフラザンカルボン酸誘導体及びこれを心臓血管系疾患の治療に使用する方法 | |
| JP2009040702A (ja) | 新規アミドプロピオン酸誘導体を含有する医薬組成物 | |
| AU2018385438B2 (en) | Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof | |
| RU2018135072A (ru) | Кристаллическая (2s,4r)-5-(5'-хлор-2'-фтор-[1,1'-бифенил]-4-ил)-2-(этоксиметил)-4-(3-гидроксиизоксазол-5-карбоксамидо)-2-метилпентановая кислота и ее применения |